Moreover, because we concurrently assessed clinical, pathologic and tumor molecular variables such as the CpG island methylator phenotype (CIMP), LINE-1 methylation, KRAS, BRAF and PIK3CA mutations, we could evaluate the effect of TGFBR2 or BAX mutation independent of these potential confounders. Here, KRAS is linked to neoplasm.